ATE382632T1 - An leukozyten bindende verbindung und diese verbindung im markierten zustand als wirkstoff enthaltende medizinische zusammensetzung - Google Patents

An leukozyten bindende verbindung und diese verbindung im markierten zustand als wirkstoff enthaltende medizinische zusammensetzung

Info

Publication number
ATE382632T1
ATE382632T1 AT03798531T AT03798531T ATE382632T1 AT E382632 T1 ATE382632 T1 AT E382632T1 AT 03798531 T AT03798531 T AT 03798531T AT 03798531 T AT03798531 T AT 03798531T AT E382632 T1 ATE382632 T1 AT E382632T1
Authority
AT
Austria
Prior art keywords
binding
compound
leukocytes
labeled
image diagnosis
Prior art date
Application number
AT03798531T
Other languages
English (en)
Inventor
I Seki
T Kawaguchi
Y Shirakami
Original Assignee
Nihon Mediphysics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Mediphysics Co Ltd filed Critical Nihon Mediphysics Co Ltd
Application granted granted Critical
Publication of ATE382632T1 publication Critical patent/ATE382632T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT03798531T 2002-09-27 2003-09-26 An leukozyten bindende verbindung und diese verbindung im markierten zustand als wirkstoff enthaltende medizinische zusammensetzung ATE382632T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002282229 2002-09-27

Publications (1)

Publication Number Publication Date
ATE382632T1 true ATE382632T1 (de) 2008-01-15

Family

ID=32040529

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03798531T ATE382632T1 (de) 2002-09-27 2003-09-26 An leukozyten bindende verbindung und diese verbindung im markierten zustand als wirkstoff enthaltende medizinische zusammensetzung

Country Status (16)

Country Link
US (1) US7220827B2 (de)
EP (1) EP1548027B1 (de)
JP (1) JP4279781B2 (de)
KR (1) KR100900178B1 (de)
CN (1) CN1684973A (de)
AT (1) ATE382632T1 (de)
AU (1) AU2003266655B2 (de)
CA (1) CA2498826A1 (de)
DE (1) DE60318466T2 (de)
DK (1) DK1548027T3 (de)
ES (1) ES2297268T3 (de)
IL (1) IL167518A (de)
NO (1) NO20051948L (de)
NZ (1) NZ538869A (de)
TW (1) TW200418880A (de)
WO (1) WO2004029080A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL367102A1 (en) 2001-05-02 2005-02-21 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
TWI332404B (en) * 2004-03-25 2010-11-01 Nihon Mediphysics Co Ltd Medicinal composition containing peptide improved in water solubility and metal labeling efficacy thereof and medicinal formulation containing metal labeled peptide
JP5175723B2 (ja) * 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
KR100630489B1 (ko) 2006-01-10 2006-10-04 주식회사 펩트론 면역반응을 조절하는 펩타이드
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
ES2539767T3 (es) * 2007-07-11 2015-07-03 Board Of Regents, The University Of Texas System Semillas y marcadores para su uso en formación de imagen
WO2011079304A1 (en) * 2009-12-23 2011-06-30 Sanford-Burnham Medical Research Institute Methods and compositions related to annexin 1-binding compounds
JP5994971B2 (ja) 2011-03-30 2016-09-21 日本メジフィジックス株式会社 炎症部位集積性化合物、核医学画像診断剤及び標識前駆体
US20220214340A1 (en) * 2019-04-28 2022-07-07 Leide Biosciences Co., Ltd. Zipper structure that helps the formation of protein dimer and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4986979A (en) * 1989-03-14 1991-01-22 Neorx Corporation Imaging tissue sites of inflammation
US5792444A (en) 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
CA2016235C (en) * 1989-05-09 2002-03-12 Alan J. Fischman Labeled chemotactic peptides to image focal sites of infection or inflammation
JPH10511701A (ja) * 1995-10-19 1998-11-10 ブラッコ インターナショナル ベスローテン フエンノートシャップ 生体組織のｎｍｒイメージングにおける標的コントラスト剤としての磁気標識化学誘引剤
AU4988900A (en) * 1999-05-05 2000-11-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The T20/dp178 and t21/dp107 are activators of human phagocyte formyl peptide receptors
CA2399032A1 (en) * 2000-02-04 2001-08-09 The Government Of The United States Of America Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection
US6955884B2 (en) * 2000-10-17 2005-10-18 Trudeau Institute, Inc. Methods for identifying compounds that inhibit CD38 activity

Also Published As

Publication number Publication date
AU2003266655B2 (en) 2009-01-08
WO2004029080A1 (ja) 2004-04-08
AU2003266655A1 (en) 2004-04-19
CN1684973A (zh) 2005-10-19
US20060057064A1 (en) 2006-03-16
US7220827B2 (en) 2007-05-22
ES2297268T3 (es) 2008-05-01
TW200418880A (en) 2004-10-01
EP1548027B1 (de) 2008-01-02
DK1548027T3 (da) 2008-05-13
DE60318466T2 (de) 2008-09-18
JPWO2004029080A1 (ja) 2006-01-26
KR100900178B1 (ko) 2009-06-02
NZ538869A (en) 2006-09-29
JP4279781B2 (ja) 2009-06-17
NO20051948L (no) 2005-06-15
DE60318466D1 (de) 2008-02-14
CA2498826A1 (en) 2004-04-08
EP1548027A4 (de) 2005-11-16
IL167518A (en) 2009-11-18
EP1548027A1 (de) 2005-06-29
KR20050053691A (ko) 2005-06-08

Similar Documents

Publication Publication Date Title
Minn et al. Enhancing CAR T-cell therapy through cellular imaging and radiotherapy
Kaplan et al. The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2.
Fabris et al. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy
Signore et al. The molecular imaging approach to image infections and inflammation by nuclear medicine techniques
Gugliotta et al. Meningoencephalitis from Borrelia miyamotoi in an immunocompromised patient
DE60318466D1 (de) An leukozyten bindende verbindung und diese verbindung im markierten zustand als wirkstoff enthaltende medizinische zusammensetzung
Tanimoto et al. Improvement of liver fibrosis by infusion of cultured cells derived from human bone marrow
De Winter et al. Promising role of 18-F-fluoro-D-deoxyglucose positron emission tomography in clinical infectious diseases
Lankinen et al. 68Ga-DOTAVAP-P1 PET imaging capable of demonstrating the phase of inflammation in healing bones and the progress of infection in osteomyelitic bones
SG149895A1 (en) Contrast agents for myocardial perfusion imaging
WO2003002156A3 (en) Contrast agents comprising metal particles encapsulated in microspheres for use in medical diagnostic imaging and therapy
Hussain et al. Cellular expression of tumour necrosis factor-α and interferon-γ in the liver biopsies of children with chronic liver disease
EP2253333A3 (de) Kontrastmittel für die blidgebende perfusion
Signore et al. The developing role of cytokines for imaging inflammation and infection
DE602004017290D1 (de) Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel
Moudgal Gonadotropins and gonadal function
DeNardo et al. Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice
Kolaczkowska et al. Angiogenic neutrophils: a novel subpopulation paradigm
Lefrère et al. The VAD chemotherapy regimen plus a G-CSF dose of 10 μg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 μg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients
Gratz et al. 99mTc-HMPAO–labeled autologous versus heterologous leukocytes for imaging infection
WO2002036173A3 (en) Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
Afzelius et al. [99mTc]-labelled interleukin-8 as a diagnostic tool compared to [18F] FDG and CT in an experimental porcine osteomyelitis model
CA2443273A1 (en) Tc and re labeled radioactive glycosylated octreotide derivatives
AASLD et al. Call to action for Liver Associations to advance progress towards viral hepatitis elimination: a focus on simplified approached to HCV testing and cure
Lee et al. Thalidomide upregulates macrophage inflammatory protein-1α in a herpes simplex virus-induced Behçet’s disease-like animal model

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1548027

Country of ref document: EP

REN Ceased due to non-payment of the annual fee